Relationship of sodium retention produced by catapres to changes in renal hemodynamics.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000618:Aminohippuric Acids / Q000652:urine; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure; D004285:Dogs; D005260:Female; D005919:Glomerular Filtration Rate; D007093:Imidazoles / Q000494:pharmacology*; D007444:Inulin / Q000652:urine; D007668:Kidney / Q000187:drug effects*; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D012039:Regional Blood Flow; D012964:Sodium / Q000378:metabolism*; D014655:Vascular Resistance
D000317:Adrenergic alpha-Antagonists; D000618:Aminohippuric Acids; D000959:Antihypertensive Agents; D007093:Imidazoles; D010643:Phenoxybenzamine; D007444:Inulin; D012964:Sodium; D009638:Norepinephrine